Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity c-reactive protein for diagnosis of atherosclerosis

American Journal of Cardiology

Volumn 109, Issue 4, 2012, Pages 515-520

  Mogelvang, Rasmus ^a,b   Pedersen, Sune H ^c   Flyvbjerg, Allan ^d   Bjerre, Mette ^d   Iversen, Allan Z ^c   Galatius, Soren ^c   Frystyk, Jan ^d   Jensen, Jan S ^a,c,e  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; OSTEOPROTEGERIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SUBCLINICAL ATHEROSCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPROTEGERIN; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 84856442666     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.09.043     Document Type: Article

References (28)

1. World Health Organization Cardiovascular diseases (CVDs) Fact sheet no. 317 2011 World Health Organization Geneva, Switzerland
2. T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon III, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr, K. Taubert, R.P. Tracy, F. Vinicor Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511 (Pubitemid 36158056)
3. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G.D. Lowe, M.B. Pepys, V. Gudnason C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397 (Pubitemid 38419992)
4. P.M. Ridker C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus J Am Coll Cardiol 49 2007 2129 2138 (Pubitemid 46783865)
5. A. Flyvbjerg Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily Nat Rev Endocrinol 6 2010 94 101
6. U.M. Breland, I. Hollan, K. Saatvedt, S.M. Almdahl, J.K. Damas, A. Yndestad, K. Mikkelsen, O.T. Forre, P. Aukrust, T. Ueland Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease Rheumatology (Oxford) 49 2010 1118 1127
7. W. Lieb, P. Gona, M.G. Larson, J.M. Massaro, I. Lipinska, J.F. Keaney Jr, J. Rong, D. Corey, U. Hoffmann, C.S. Fox, R.S. Vasan, E.J. Benjamin, C.J. O'Donnell, S. Kathiresan Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality Arterioscler Thromb Vasc Biol 30 2010 1849 1854
8. M. Abedin, T. Omland, T. Ueland, A. Khera, P. Aukrust, S.A. Murphy, T. Jain, U. Gruntmanis, D.K. McGuire, J.A. de Lemos Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study) Am J Cardiol 99 2007 513 518 (Pubitemid 46215559)
9. M. Appleyard, A.T. Hansen, P. Schnohr, G. Jensen, J. Nyboe The Copenhagen City Heart Study A book of tables with data from the first examination (197678) and a five-year follow-up (1981-83) Scand J Soc Med 170 1989 1 160
10. P. Schnohr, G. Jensen, P. Lange, H. Scharling, M. Appleyard The Copenhagen City Heart Study Tables with data from the third examination 199194 Eur Heart J 3 2001 1 83
11. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252 (Pubitemid 37553153)
12. A.L. Peters, M.B. Davidson, D.L. Schriger, V. Hasselblad Meta-Analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels JAMA 276 1996 1246 1252 (Pubitemid 26337708)
13. K.G. Rowley, M. Daniel, K. O'Dea Screening for diabetes in indigenous populations using glycated haemoglobin: sensitivity, specificity, post-test likelihood and risk of disease Diabet Med 22 2005 833 839 (Pubitemid 40942578)
14. L.M. Rasmussen, L. Tarnow, T.K. Hansen, H.H. Parving, A. Flyvbjerg Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients Eur J Endocrinol 154 2006 75 81 (Pubitemid 43250739)
15. G. Assmann, P. Cullen, H. Schulte Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study Circulation 105 2002 310 315 (Pubitemid 34106178)
16. R. Ross Atherosclerosisan inflammatory disease N Engl J Med 340 1999 115 126
17. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. Macfadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
18. R.C. Shroff, V. Shah, M.P. Hiorns, M. Schoppet, L.C. Hofbauer, G. Hawa, L.J. Schurgers, A. Singhal, I. Merryweather, P. Brogan, C. Shanahan, J. Deanfield, L. Rees The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis Nephrol Dial Transplant 23 2008 3263 3271
19. K. Nitta, T. Akiba, K. Suzuki, K. Uchida, R. Watanabe, K. Majima, T. Aoki, H. Nihei Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis Am J Kidney Dis 44 2004 680 688 (Pubitemid 39237612)
20. A. Luckish, R. Cernes, M. Boaz, D. Gavish, Z. Matas, A. Fux, M. Shargorodsky Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors Bone 43 2008 279 283
21. P. Olesen, T. Ledet, L.M. Rasmussen Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha Diabetologia 48 2005 561 568 (Pubitemid 40487304)
22. G.D. Xiang, H.L. Sun, L.S. Zhao Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients Diabetes Res Clin Pract 76 2007 199 206
23. G.D. Xiang, L. Xu, L.S. Zhao, L. Yue, J. Hou The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes Diabetes 55 2006 2126 2131 (Pubitemid 44509988)
24. J. Golledge, A.S. Leicht, R.G. Crowther, S. Glanville, P. Clancy, K.S. Sangla, W.L. Spinks, F. Quigley Determinants of endothelial function in a cohort of patients with peripheral artery disease Cardiology 111 2008 51 56
25. S. Kiechl, G. Schett, G. Wenning, K. Redlich, M. Oberhollenzer, A. Mayr, P. Santer, J. Smolen, W. Poewe, J. Willeit Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease Circulation 109 2004 2175 2180 (Pubitemid 38625393)
26. A.G. Semb, T. Ueland, P. Aukrust, N.J. Wareham, R. Luben, L. Gullestad, J.J. Kastelein, K.T. Khaw, S.M. Boekholdt Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003 Arterioscler Thromb Vasc Biol 29 2009 975 980
27. Z. Ali, A.A. Ellington, T.H. Mosley Jr, I.J. Kullo Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites Atherosclerosis 206 2009 575 580
28. H.E. Resnick, R.S. Lindsay, M.M. McDermott, R.B. Devereux, K.L. Jones, R.R. Fabsitz, B.V. Howard Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study Circulation 109 2004 733 739 (Pubitemid 38222892)